Phase 3 Update: Levosimendan Fails to Ease Breathing Problems in ALS Patients
Orion Corporation’s oral therapy levosimendan (ODM-109) failed to preserve lung function and overall functionality in people with amyotrophic lateral sclerosis (ALS), data from the Phase 3 REFALS clinical trial show. “We would like to express our warmest thanks to the patients, carers and investigators for participating in the REFALS…